Public Release: 

InSysBio LLC announce renewal of agreement with ASTEX Pharmaceuticals Inc.

Institute for Systems Biology Moscow

Moscow, Russia, July 25, 2017 - InSysBio LLC , one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.

Within the framework of this cooperation, InSysBio provides priority support for ASTEX research. This gives an opportunity to access the best practices of InSysBio in the field of QSP modeling, as well as significantly reduce the time of initiation and execution of projects.

The renewal of the ASTEX agreement once again shows that QSP is a necessary technology to support discovery and development of new drugs in oncology and immuno-oncology therapeutic areas. Such an approach improves all stages of the development: it helps to make strategic GO/ NO GO decisions for research, prioritize targets and compounds, interpret results from animal studies and select optimal design(s) for clinical trials.

"We are very pleased ASTEX has chosen to renew our multi-year Master Service Agreement. It underscores that our partners are satisfied with our services and would like to extend this fruitful and reliable collaboration," said Founder and CEO Oleg Demin, PhD.

###

About InSysBio

InSysBio, Ltd. is a leading R&D company providing services for mathematical modeling in drug research and development. InSysBio is one of the pioneers in quantitative system pharmacology (QSP) modeling and simulation services and has been working on the market for more than 10 years. The company's aim is to assist right decisions on the critical stages of drug research and development. InSysBio team continuously improves methods and tools for biological modeling. Moreover, company works with students and postgraduates forming professional community of QSP-modelers. Company has published a lot of scientific studies, and has presented at major international conferences of the field. The InSysBio innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharma industry.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.